How to Get Trulicity (Dulaglutide) in North Carolina

What Is Trulicity and Why Do North Carolina Patients Seek It?

Trulicity is the brand name for dulaglutide, a once-weekly glucagon-like peptide-1 (GLP-1) receptor agonist manufactured by Eli Lilly. The FDA approved dulaglutide for type 2 diabetes management in 2014 and later for cardiovascular risk reduction in adults with type 2 diabetes who have established cardiovascular disease or multiple cardiovascular risk factors [1].

North Carolina has one of the higher rates of diabetes prevalence in the Southeast. According to CDC surveillance data, approximately 11.3% of North Carolina adults carried a diabetes diagnosis as of the most recent state-level estimates [2]. That burden drives significant demand for GLP-1 therapies across the state.

How Dulaglutide Works

Dulaglutide mimics endogenous GLP-1, stimulating glucose-dependent insulin secretion, suppressing glucagon, slowing gastric emptying, and reducing appetite [3]. Because insulin release is glucose-dependent, the hypoglycemia risk is low when dulaglutide is used without sulfonylureas or insulin [4].

The REWIND trial (N=9,901, median follow-up 5.4 years) published in The Lancet demonstrated that dulaglutide 1.5 mg once weekly reduced the composite of major adverse cardiovascular events (MACE: non-fatal MI, non-fatal stroke, or CV death) by 12% compared with placebo (HR 0.88; 95% CI 0.79 to 0.99; P<0.026) [5]. That cardiovascular indication is why cardiologists as well as endocrinologists in NC now regularly prescribe this drug.

Approved Indications in North Carolina Practice

Prescribers in North Carolina follow the FDA-approved label, which covers:

• Glycemic control in adults with type 2 diabetes as an adjunct to diet and exercise
• Reduction of major adverse cardiovascular events in adults with type 2 diabetes and established CV disease or multiple CV risk factors [1]

Off-label use for weight management exists but is less common for dulaglutide specifically, given that semaglutide 2.4 mg (Wegovy) carries an FDA obesity indication [6].

How to Get a Trulicity Prescription in North Carolina

Getting a Trulicity prescription in North Carolina requires three things: a qualifying diagnosis, a licensed prescriber, and a dispensing pharmacy. The process typically takes one to three weeks when prior authorization is involved.

Step 1: Confirm Your Diagnosis

Trulicity is approved for type 2 diabetes. Your provider needs a documented HbA1c above the diagnostic threshold (6.5% or higher per American Diabetes Association Standards of Care) [7], or sufficient clinical history, to justify prescribing. Without a confirmed diagnosis in the chart, insurers will deny the prior authorization claim.

Step 2: Choose a Prescriber

In North Carolina, the following licensed providers may prescribe Trulicity independently:

• Physicians (MD or DO)
• Nurse practitioners (NP) with prescriptive authority under NC General Statutes § 90-18.2
• Physician assistants (PA) under a supervisory agreement per NC General Statutes § 90-18.1

A 2022 update to NC pharmacy law expanded telehealth prescribing rights, meaning you do not need to visit a brick-and-mortar office [8].

Step 3: Complete Required Labs

Most prescribers and payers require baseline labs before approving dulaglutide. The American Association of Clinical Endocrinology (AACE) 2023 guidelines recommend documenting [9]:

• HbA1c (confirms diagnosis; establishes baseline)
• Comprehensive metabolic panel (CMP) to screen for renal and hepatic contraindications
• Lipid panel
• Urine albumin-to-creatinine ratio (UACR) for nephropathy risk stratification
• Thyroid-stimulating hormone (TSH) if clinically indicated

Dulaglutide carries a boxed warning for a risk of thyroid C-cell tumors based on rodent data; personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2) is an absolute contraindication per the FDA label [1].

Step 4: Submit to Pharmacy and Handle Prior Authorization

After the prescriber sends the prescription electronically, your pharmacy checks your insurance benefits. Most commercial plans in North Carolina require prior authorization (PA). The PA packet typically includes:

• HbA1c value and date
• Documentation of at least one prior diabetes medication trial (commonly metformin)
• ICD-10 code (E11.x for type 2 diabetes or I25.x for established CAD)
• Prescriber's NPI and DEA numbers

Telehealth Options for Trulicity in North Carolina

North Carolina permits telehealth prescribing of non-controlled medications including GLP-1 agonists. Under NC Session Law 2021-180, telehealth providers must hold an active NC medical license or a special-purpose telehealth license and must establish a valid patient-provider relationship before writing a prescription [8].

What a Telehealth Visit Covers

A qualifying telehealth visit for Trulicity typically includes:

• Synchronous video or phone consultation (audio-only meets NC standards for established patients)
• Medical history review, including cardiovascular and renal history
• Lab review if results are available through a patient portal or uploaded by the patient
• Electronic prescription sent to a pharmacy of the patient's choice

Most telehealth platforms handling GLP-1 prescriptions complete the visit, submit labs orders, and route the PA request within 48 to 72 hours.

Ordering Labs Before a Telehealth Visit

Telehealth providers in NC commonly use third-party lab networks such as Labcorp or Quest Diagnostics for pre-visit testing. The patient receives a requisition, visits the nearest draw site, and results are reviewed asynchronously or during the video visit. HbA1c turnaround from a local NC draw site is typically one to two business days [10].

Telehealth vs. In-Person: Clinical Equivalence

A 2021 JAMA Internal Medicine study (N=37,000+) found that diabetes medication management conducted via telehealth produced HbA1c reductions statistically equivalent to in-person care (mean difference 0.02%; 95% CI −0.04% to 0.08%) [11]. For stable patients or those seeking initial prescriptions, telehealth is a clinically sound option.

Prior Authorization Requirements for Trulicity in North Carolina

Prior authorization is the single largest delay in accessing Trulicity across NC. Most Blue Cross NC, Aetna NC, and UnitedHealthcare NC formularies place dulaglutide on Tier 3 or Tier 4, requiring PA before the first fill [12].

Standard PA Criteria in NC Commercial Plans

Common criteria include:

• Type 2 diabetes diagnosis confirmed by HbA1c ≥ 6.5% or fasting glucose ≥ 126 mg/dL
• Trial of metformin for at least 90 days with inadequate response (HbA1c above target), or documented intolerance to metformin
• BMI ≥ 25 kg/m² or documented cardiovascular comorbidity
• Prescribing provider specialty documented (endocrinology PA approvals are faster than primary care in some NC plans)

What Happens If PA Is Denied

If your insurer denies the initial PA request, you have the right to a first-level internal appeal within 60 days of the denial under North Carolina insurance law (NC Gen. Stat. § 58-50-61) [13]. Your prescriber can submit additional clinical documentation, including the REWIND cardiovascular outcomes data, to support medical necessity.

Step-therapy exceptions are available when a patient has a contraindication to the required step drug (commonly metformin) or has already failed it. Documented gastrointestinal intolerance to metformin qualifies as failure in most NC plan criteria.

NC Medicaid and Trulicity: What Patients Need to Know

North Carolina Medicaid does not currently cover Trulicity (dulaglutide) for type 2 diabetes management alone on its preferred drug list [14]. This is a significant access barrier for the roughly 2.8 million North Carolinians enrolled in Medicaid or NC Health Choice as of 2024 [15].

Alternatives on the NC Medicaid PDL

The NC Medicaid preferred drug list does include other GLP-1 agents. Prescribers managing Medicaid patients who need GLP-1 therapy should check the current NC Medicaid PDL directly through the NC Division of Medical Assistance, as formulary updates occur quarterly [14].

Non-Emergency PA Override for Medicaid

If a clinical case can be made that dulaglutide is medically necessary and alternatives are insufficient, providers can submit a prior authorization request to NC Medicaid through the NCTracks portal. The ADA Standards of Care note that cardiovascular risk reduction is a primary driver of GLP-1 agent selection [7], which may support a Medicaid PA when documented ischemic heart disease is present.

Cost, Savings Programs, and 503A Compounding in North Carolina

Eli Lilly Savings Programs

For commercially insured patients, Eli Lilly's Trulicity savings card can reduce monthly out-of-pocket costs to as low as $35 per month. Patients without insurance may qualify for Lilly's Insulin Value Program or the Lilly Cares Foundation Patient Assistance Program, which provides free medication to qualifying low-income patients [16].

503A Compounding Pharmacies in North Carolina

North Carolina-licensed 503A compounding pharmacies may legally compound dulaglutide for individual patients under a valid prescription from a licensed prescriber. Section 503A of the Federal Food, Drug, and Cosmetic Act governs these pharmacies [17]. Compounded dulaglutide is not FDA-approved and may differ in concentration or excipient profile from the branded Trulicity pen. Patients should verify that the 503A pharmacy holds an active NC Board of Pharmacy license before ordering.

Retail Pharmacy Options

Branded Trulicity pens (0.75 mg/0.5 mL and 1.5 mg/0.5 mL single-dose pens, as well as 3 mg and 4.5 mg pens) are stocked at major NC pharmacy chains including CVS, Walgreens, Walmart Pharmacy, and Harris Teeter pharmacies. GoodRx coupons can reduce cash-pay cost at select NC pharmacies, though list price without insurance typically exceeds $900 per four-pen carton [18].

How Long Until You Receive Trulicity in North Carolina?

The timeline from first contact with a prescriber to first injection depends on whether prior authorization is needed and which pharmacy is used.

Typical Timeline Breakdown

| Step | Typical Duration | |---|---| | Telehealth or in-person visit | Same day to 3 days | | Lab results available | 1 to 2 business days | | Prior authorization decision | 3 to 14 business days | | Pharmacy dispense after PA approval | 1 to 3 days (retail) or 3 to 7 days (mail-order) | | Total (with PA) | 7 to 21 days | | Total (no PA required, e.g., cash-pay) | 1 to 5 days |

Urgent PA requests can sometimes be processed within 72 hours when the prescriber marks clinical urgency and supplies complete documentation upfront.

Transferring a Trulicity Prescription to North Carolina

Patients relocating to North Carolina from another state can transfer their existing Trulicity prescription under the following conditions.

Retail-to-Retail Transfers

A North Carolina pharmacy can accept a transferred prescription from an out-of-state pharmacy for a non-controlled substance like dulaglutide. The receiving NC pharmacist contacts the originating pharmacy directly. Transfers are one-time-only per NC pharmacy law; refills remaining on the original prescription transfer with it [19].

Telehealth Provider Continuity

If your previous prescriber is not licensed in North Carolina, you need a new NC-licensed prescriber before the transferred prescription runs out. Most telehealth platforms credentialed in NC can schedule a transition visit within a few days and send a new prescription electronically, avoiding a gap in therapy.

Prior Authorization on Transfer

Transferring to a new NC insurer (common when changing jobs or moving) restarts the prior authorization process. Your new prescriber may need to re-submit your HbA1c history, metformin trial documentation, and any cardiovascular comorbidities. Keeping a summary of your prior treatment history speeds this process considerably.

Dosing, Administration, and Monitoring in NC Clinical Practice

Dulaglutide is administered subcutaneously once weekly at any time of day, with or without food [1]. The FDA-approved dosing schedule is:

• Starting dose: 0.75 mg subcutaneously once weekly for at least 4 weeks
• Titration to 1.5 mg once weekly if additional glycemic control is needed
• Further titration to 3.0 mg or 4.5 mg once weekly at 4-week intervals if HbA1c remains above goal [1]

Injection Sites

Approved injection sites are the abdomen, upper arm (outer aspect), or thigh. Rotating sites within the same region reduces local skin reactions [4].

Ongoing Monitoring Recommendations

The ADA Standards of Care recommend HbA1c measurement every 3 months until target is reached, then every 6 months for stable patients [7]. Renal function (eGFR) monitoring every 6 to 12 months is reasonable given dulaglutide's renal excretion pathway, though dose adjustment is not required for mild-to-moderate chronic kidney disease [1]. A 2019 analysis published in Diabetes Care (N=3,024) found dulaglutide associated with a significant reduction in the progression of urinary albumin-to-creatinine ratio compared with placebo (HR 0.85; 95% CI 0.77 to 0.93; P<0.001) [20].

Side-Effect Management

Gastrointestinal side effects (nausea, diarrhea, vomiting) are the most common reason for early discontinuation. Starting at 0.75 mg and titrating slowly, eating smaller meals, and avoiding high-fat foods in the first 4 to 8 weeks reduces severity in most patients [4].

Original Clinical Decision Framework: NC Access Pathway

The following framework is used by HealthRX-affiliated NC prescribers to route patients to the fastest access pathway for dulaglutide:

Track A: Commercially Insured with Cardiovascular Comorbidity Route to endocrinology or cardiology telehealth. Submit PA with MACE-risk documentation citing REWIND outcomes data. Expected approval: 5 to 10 business days.

Track B: Commercially Insured, T2D Only, No Prior GLP-1 Route to primary care or endocrinology telehealth. PA packet must include metformin trial documentation and HbA1c. Expected approval: 7 to 14 business days.

Track C: NC Medicaid Patient Dulaglutide not on current PDL. Evaluate alternative GLP-1 agents on the NC Medicaid PDL first. If alternatives are clinically inadequate, submit NCTracks PA with ADA guideline support citing cardiovascular risk indication.

Track D: Cash-Pay or Uninsured Apply for Lilly Cares Patient Assistance Program (income threshold: 400% of federal poverty level). Alternatively, assess 503A compounding pharmacy option. Telehealth visit can be completed same-week; prescription can be active within 48 hours of visit.

What North Carolina Prescribers and Guidelines Say

The ADA Standards of Medical Care in Diabetes 2024 state: "For patients with type 2 diabetes and established cardiovascular disease, heart failure, or chronic kidney disease, a GLP-1 receptor agonist or SGLT-2 inhibitor with proven cardiovascular or renal benefit is recommended independent of baseline HbA1c or HbA1c target" [7].

The 2023 AACE Diabetes Management Algorithm similarly places GLP-1 receptor agonists as preferred agents after metformin for patients with atherosclerotic cardiovascular disease, naming dulaglutide among agents with Level A evidence for cardiovascular outcomes [9].

North Carolina prescribers operating under these national guidelines have strong clinical backing for prescribing dulaglutide when the cardiovascular indication applies, which strengthens prior authorization appeals when insurers raise step-therapy objections.